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Background: Myocardial infarction (MI) is a serious complication of Coronary Artery Disease (CAD). Previous studies
have identified genetic variants on chromosome 9p21 and 6p24 that are associated with CAD, but further studies
need to be conducted to investigate whether these genetic variants are associated with the pathogenesis of MI.
We therefore performed this study to assess the association between the risk of MI and SNP rs10757274 on chromosome
9p21 and SNP rs6903956 on chromosome 6p24, and to explore the gene-environment interactions in a Chinese
population.
Methods: A hospital-based case–control study, consisting of 502 MI patients and 308 controls, was conducted in a
Chinese population. Demographic, behavioral information and clinical characteristics were collected, and genotyping
of the two SNPs was performed using single base primer extension genotyping technology. The unconditional
logistic regression (ULR) method was adopted to assess the association of the two SNPs with MI risk. Both
generalized multifactor dimensionality reduction (GMDR) and ULR methods were applied to explore the effect
of gene-environment interactions on the risk of MI.
Results: After adjusting for covariates, it was observed that SNP rs10757274 on chromosome 9p21 was significantly
associated with MI. Compared with subjects carrying the AA genotype, subjects carrying the GA or GG genotypes had
a higher MI risk (ORa = 1.52, 95% CI:1.06–2.19, pa = 0.0227; ORa = 2.40, 95% CI:1.51–3.81, pa = 0.0002, respectively).
Furthermore, a two-factor gene-environment interaction model of CDKN2A/B (rs10757274) and type 2 diabetes mellitus
(T2DM) was identified to be the best model by GMDR (p = 0.0107), with a maximum prediction accuracy of 59.18%,
and a maximum Cross-validation Consistency of 10/10. By using the ULR method, additive interaction analysis found
that the combined effect resulted in T2DM-positive subjects with genotype GG/GA having an MI risk 4.38 times that of
T2DM-negative subjects with genotype AA (ORadd = 4.38, 95% CI:2.56–7.47, padd < 0.0001).
Conclusions: These results show that gene polymorphism of CDKN2A/B (rs10757274) is associated with MI risk in a
Chinese population. Furthermore, T2DM is likely to have an interaction with CDKN2A/B (rs10757274) that contributes to
the risk of MI.* Correspondence: lijianping@medmail.com.cn; dafangchen@bjmu.edu.cn
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It has been reported that the global endemic of Coronary
Artery Disease (CAD) is the leading cause of morbidity
and mortality worldwide, due to serious complications
such as myocardial infarction (MI) [1,2]. Most researchers
agree that, similarly to other complex diseases, multiple en-
vironmental factors, genetic factors and gene-environment
interactions play important roles in determining the onset
and development of CAD/MI [3]. There are many well-
recognized environmental risk factors such as smoking,
physical activity and body mass index (BMI). Genetic fac-
tors have also been considered to be substantial risk con-
tributors to the pathogenesis of CAD/MI [4,5]. Although
previous studies have shown that the heritability of CAD
ranges from approximately 40 to 60%, the genetic mechan-
ism underlying the inherited component of CAD/MI is still
not fully characterized [6].
In the past decade, there have been many studies on
linkage and candidate gene association, however, these
have only identified a limited number of genetic variants
involved in the pathogenesis of CAD/MI. Genome-wide
association studies (GWAS) have been a new approach
since the completion of the Human Genome Project and
the International HapMap Project, and have provided
improved resolution in identifying genetic factors in re-
lation to complex diseases. To date, many genome-wide
studies have revealed that several genomic regions are
strongly associated with an increased risk of CAD/MI
[7-14], and it has been generally accepted that the asso-
ciation between genetic variants on chromosome 9p21
and the risk of CAD is the most robustly replicated find-
ing in different ethnic populations [15-18]. However,
several other studies have shown inconsistent results
when the association between these genetic variants and
MI was examined [19,20]. Recently, a Chinese GWAS
reported that chromosome 6p24 contains a novel sus-
ceptibility locus associated with CAD [14]. Some previous
single studies have also suggested that genetic variants as-
sociated with cardiovascular disease might interact with
hypertension or glycemic control [21,22]. Therefore, we
chose to study SNP rs10757274 on chromosome 9p21
and SNP rs6903956 on chromosome 6p24, to identify the
association between these two susceptible genes and the
risk of MI, and to explore gene-environment interactions
in a Chinese population.
Methods
Study population
This project was designed as a hospital-based case–control
study. Between June 2012 and May 2013, a total of 810
consecutive unrelated adult patients at Peking University
First Hospital (Beijing, China) were enrolled in the study.
Of these subjects, 502 patients undergoing coronary angi-
ography for suspected or known coronary atherosclerosiswere diagnosed with MI according to the universal defin-
ition of myocardial infarction [23], while 308 subjects were
considered as the control group, who underwent coronary
angiography for other reasons (mainly valvular heart dis-
ease) and had completely normal coronary arteries. Quanto
software was used to measure the statistical power of this
study; according to the frequencies of the minor allele
(listed on NCBI) and the genetic effects that have been re-
ported for these two SNPs, the statistical power of this
study based on the current sample size is more than 0.90.
The study was approved by the Ethics Committee of the
Peking University Health Science Center, and all the sub-
jects provided written informed consent for participation.Information collection
Demographic, behavioral information and clinical char-
acteristics were collected from physicians and hospital
records, including age, gender, ethnicity, smoking and
drinking habits and some medical history information. A
smoking habit was defined as current active smokers or
those with a smoking history of at least10 packs per year,
while a drinking habit was defined as consuming more
than 50 g of alcohol per week for at least 6 months.
Weight and height were measured when the subjects
were lightly clothed and barefoot, and the BMI was cal-
culated as the weight divided by the square of the height
(kg/m2)). Overnight fasting blood samples were obtained
from all participants, and measurements of the plasma
concentrations of glucose, total cholesterol (TC, mmol/L),
low density lipoprotein cholesterol (LDL-C, mmol/L),
high density lipoprotein cholesterol (HDL-C, mmol/L)
and triglyceride (TG, mmol/L) were conducted in
the clinical laboratory of the Peking University First
Hospital according to the standard biochemical methods.
Combined with laboratory findings, type two diabetes
mellitus (T2DM) was diagnosed according to the WHO
diagnostic criteria from 1999 [24]; hypertension was
defined as systolic blood pressure ≥140 mmHg and/or
diastolic blood pressure ≥90 mmHg based on the average
of two separate measurements, or current antihyperten-
sive treatment; hyperlipidemia was diagnosed as fasting
total cholesterol ≥200 mg/dL or low-density lipoprotein
cholesterol ≥130 mg/dL.DNA preparation
EDTA anti-coagulated blood samples were drawn from
every participant, and genomic DNA was extracted from
the participants’ peripheral blood leucocytes by using
the protein precipitation method following standard pro-
cedures. Each DNA sample was quantified using a Nano-
photometer (Implen, Germany) and was diluted to a final
concentration of 50 ng/uL.
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Genotyping of two SNPs (rs6903956 and rs10757274)
was performed using the single base primer extension
genotyping technology with the GenomeLab SNPstream
genotyping system (Beckman Coulter Inc, Fullerton, CA,
USA) following the manufacturer’s protocol [25]. Both
of the SNPs had a call rate of greater than 95%, 10% of
the blind duplicate samples were genotyped repeatedly
and the rate of consistency was 100%.
Statistical analysis
The descriptive and association analyses were performed
using the SAS 9.1 software (SAS Institute Inc., Cary, NC).
The continuous variables were shown as Mean ± SD, a
two-sample t-test was adopted to compare their means.
The comparison of categorical variables and testing of the
Hardy-Weinberg Equilibrium (HWE) at each polymorphic
locus in the control group was conducted using Pearson’s
χ2 test. Unconditional logistic regression (ULR) was per-
formed to estimate the association (Odds ratios (ORs) and
95% confidence intervals (CIs)) between individual poly-
morphisms and MI, adjusting for potential confounders,
including gender, age, ethnicity, BMI, smoking and drink-
ing habits. High dimensional gene-environment interac-
tions were examined using the generalized multifactor
dimensionality reduction method (GMDR, version 0.7,
obtained from http://www.medicine.virginia.edu/clinical/
departments/psychiatry/sections/neurobiologicalstudies/
genomics/gmdr-software-request) [26], adjusting for age,
gender, ethnicity, BMI, smoking and drinking habits as
covariates. GMDR is a nonparametric method reducing
high-dimensional data into one dimension. In this study,
one- to five-factor models were constructed and the model
with the highest prediction accuracy was defined as the
“best model”. If the model was considered to be significant
using the sign statistical test (p < 0.05), then a 1000 times
permutation test was performed to validate the results. One
dimensional multiplicative interaction was detected by
ULR, adjusting for the potential confounders mentioned
above. One dimensional additive interaction was estimated
using the “Biological interaction calculating Excel” provided
by Andersson et al. [27]. For two dichotomized risk factors,
let OR01/OR10 represent exposure of each risk factor alone,
let OR11 represent exposure of both risk factors, and let
OR00 represent absence of both risk factors, which was
used as the reference category. Three statistical indica-
tors were calculated: relative excess risk of interaction
(RERI =OR11 - (OR01 +OR10 -1)), attributable proportion
of interaction (API = RERI/OR11), and the synergy index
(S = (OR11 - 1)/[(OR01 - 1) + (OR10 - 1)]), along with
their 95% CIs, to measure the additive interaction. If
the 95% CIs of RERI and API did not include 0 and the
95% CI of the S index did not include 1, it can be con-
sidered that an additive interaction exists.Results
Demographic, behavioral information and clinical
characteristics of participants
A total of 810 unrelated Chinese subjects were enrolled
in this study. The minimum and maximum ages among
the participants were 28 and 88, respectively. The aver-
age age of the 502 cases was (63.66 ± 11.57) years, and
the average age of the 308 controls was (61.87 ± 10.39)
years. 64.92% of participants were male and 35.08% were
female. The distributions of demographic, behavioral in-
formation and clinical characteristics of the subjects are
listed in Table 1. There were no significant differences
between the MI group and the control group in terms of
mean BMI and distributions of ethnicity, hypertension
and hyperlipidemia, while the mean age and frequencies
of male gender, T2DM-positive, and smoking and drink-
ing habits-positive were significantly higher in MI pa-
tients than in controls.
Association analysis of genetic polymorphisms with MI
Two SNPs, ADTRP (rs6903956) and CDKN2A/B (rs107
57274) were studied in our association analysis. Both
of their genotype distributions in the control group
conformed to the HWE (χ2 = 2.756, p = 0.097; χ2 = 0.968,
p = 0.325; respectively), which indicated these participants
were from a homogeneous group. The genotype distribu-
tions of the two SNPs between MI patients and controls
and their association with MI risk are available in Table 2,
while the univariate associations between each of the two
SNPs and the clinical characteristics listed in Table 1 for
cases and controls are included in the Additional file 1:
Table S1 and S2. Taking the subjects carrying the GG
genotype for ADTRP (rs6903956) as a reference, the sub-
jects carrying genotype AA/GA showed an increased risk
of MI (OR = 1.51, 95% CI:1.01–2.23, p = 0.0423), but after
adjusting for confounding factors including age, gender,
ethnicity, BMI, smoking and drinking habits, the associ-
ation between ADTRP (rs6903956) and MI risk was in-
significant (OR = 1.49, 95% CI:0.97–2.29, p = 0.0678).
According to the genetic effect and minor allele fre-
quency of rs6903956 observed in this study, the statis-
tical power based on the current sample size is 0.73.
For CDKN2A/B (rs10757274), both before and after
adjusting for confounding factors mentioned above, the
subjects carrying GA or GG genotypes were all associated
with MI risk (ORa = 1.52, 95% CI:1.06–2.19, pa = 0.0227;
ORa = 2.40, 95% CI:1.51–3.81, pa = 0.0002; respectively),
compared with subjects with the AA genotype. For
rs10757274, the statistical power based on the current
sample size is 0.97.
Gene-environment interactions analysis
First, GMDR was used to explore the gene-environment in-
teractions. ADTRP (rs6903956), CDKN2A/B (rs10757274)
Table 1 Demographic, behavioral information and clinical
characteristics of participants






Age 61.87 ± 10.39 63.66 ± 11.57 2.2823 0.0228
BMI (kg/m2) 25.84 ± 3.53 25.73 ± 3.09 0.4673 0.6404
Gender
Male 47.73 77.09 73.2707 <.0001
Female 52.27 22.91
Ethnicity
Chinese Han 94.48 96.81 2.6567 0.1031
Ethnicity minority 5.52 3.19
Smoking habit
No 63.96 36.65 57.1381 <.0001
Yes 36.04 63.35
Drinking habit
No 74.68 61.75 14.3438 0.0002
Yes 25.32 38.25
T2DM
No 75.97 61.35 18.4275 <.0001
Yes 24.03 38.65
Hypertension
No 35.71 32.07 1.1376 0.2862
Yes 64.29 67.93
Hyperlipidemia
No 60.06 61.55 0.1778 0.6732
Yes 39.94 38.45
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hyperlipidemia) were included in the gene-environment
interactions analysis, adjusting for age, gender, ethni-
city, BMI, and smoking and drinking habits as covari-
ates. The results of the GMDR analysis for one-factor
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a: Adjusting for age, gender, ethnicity, BMI, smoking and drinking habits as covariatthese results, the two-factor interaction model of
CDKN2A/B (rs10757274) and T2DM was identified to
be the best model, with a maximum prediction accuracy
of 59.18%, and a maximum Cross-validation Consistency
(CVC) of 10/10. This model was identified as significant
using the sign test (p = 0.0107) and validated by a 1000
times permutation test (p < 0.001). These results indicate
that a potential gene-environment interaction is likely to
exist between T2DM and CDKN2A/B (rs10757274) af-
fecting MI risk in this study.
Second, to further reveal the potential gene-environment
interaction mentioned above, ULR analysis was conducted
to explore the possible multiplicative or additive gene-
environment interactions between T2DM and CDKN2A/B
(rs10757274) affecting MI risk. As shown in Table 4, there
were no gene-environment multiplicative interactions be-
tween T2DM and CDKN2A/B (rs10757274) affecting MI
risk (ORmulti = 1.63, 95% CI:0.78–3.44, pmulti = 0.197). After
adjusting for age, gender, ethnicity, BMI, smoking and
drinking habits as covariates, T2DM-negative subjects
with the genotype GG/GA had a MI risk of 1.60 times
that of T2DM-negative subjects carrying the genotype
AA (ORadd = 1.60, 95% CI:1.04–2.46), and it was statis-
tically significant (padd = 0.0329); T2DM-positive sub-
jects with genotype AA had a MI risk of 1.68 times that of
T2DM-negative subjects carrying genotype AA (ORadd =
1.68, 95% CI:0.92 − 3.08), but it was not statistically signifi-
cant (padd = 0.0943). The combined effect resulted in
T2DM-positive subjects with genotype GG/GA having
an MI risk of 4.38 times that of T2DM-negative subjects
carrying genotype AA (ORadd = 4.38, 95% CI:2.56 − 7.47),
and this was statistically significant (padd < 0.0001). Be-
cause the 95% CIs of RERI and API did not include 0, and
the 95% CI of S did not include 1 (RERI = 2.10, 95%
CI:0.18 − 4.03; API = 0.48, 95% CI:0.19 − 0.77; and S =
2.65, 95% CI:1.01 − 6.94, respectively), it can be considered
that an additive gene-environment interaction exists be-
tween T2DM and CDKN2A/B (rs10757274) affecting the
risk of MI.I risk
equencies (%) Without adjustment With adjustment
MI patients (N = 502) OR (95% CI) p ORa (95% CI) pa
79.30 reference
18.74 1.50 (1.00,2.27) 0.0525 1.55 (0.99,2.43) 0.0556
1.96 1.53 (0.47,5.03) 0.4813 1.04 (0.30,3.59) 0.9522
20.70 1.51 (1.01,2.23) 0.0423 1.49(0.97,2.29) 0.0678
23.54 reference
52.52 1.43 (1.02,1.99) 0.0374 1.52(1.06,2.19) 0.0227
23.94 2.10 (1.37,3.22) 0.0007 2.40 (1.51,3.81) 0.0002
76.46 1.58 (1.15,2.18) 0.0045 1.72 (1.22,2.43) 0.0020
es.





T2DM 0.5815 10/10 0.0010 <0.001
T2DM, rs10757274 0.5918 10/10 0.0107 <0.001
T2DM, rs10757274, rs6903956 0.5796 10/10 0.0107 <0.001
T2DM, hyperlipidemia,
rs10757274, rs6903956
0.5815 9/10 0.0547 <0.001
T2DM, hyperlipidemia, hypertension,
rs10757274, rs6903956
0.5692 10/10 0.0547 0.008
aAdjusting for age, gender, ethnicity, BMI, smoking and drinking habits
as covariates.
psign: p-value from sign test.
pperm: p-value from 1000 times permutation test.
Zhang et al. BMC Cardiovascular Disorders 2014, 14:170 Page 5 of 7
http://www.biomedcentral.com/1471-2261/14/170Discussion
Due to the fact that MI is the main complication of
CAD and both of these diseases share common risk fac-
tors, both genetic variants and environmental risk fac-
tors associated with CAD are expected candidates
affecting the risk of MI. In this case–control study, we
chose two previously reported SNPs representing the
genetic variants on 9p21 and 6p24 to investigate the as-
sociation with MI. Our results indicate that a genetic
variant of CDKN2A/B (rs10757274) on 9p21 is associ-
ated with MI after adjusting for conventional confound-
ing factors, which consistently supports former results
[10,28,29]. Further gene-environment interactions for
ADTRP (rs6903956), CDKN2A/B (rs10757274), hyperten-
sion, dyslipidemia and T2DM were explored by GMDR and
ULR methods, and the results from GMDR indicate that a
gene-environment interaction is likely to exist between
CDKN2A/B (rs10757274) and T2DM affecting the risk of
MI. Further analytic results from ULR consistently support
the existence of potential additive gene-environment inter-
actions between CDKN2A/B (rs10757274) and T2DM, with
a combined effect of increasing the risk of MI for T2DM-Table 4 Multiplicative and additive gene-environmental inter
(rs10757274) on MI risk
Frequencies (%)
Genotype T2DM Controls (N = 308) MI patients (N = 502
rs10757274
AA No 22.52 12.67
GG/GA 53.31 48.69





aAdjusting for age, gender, ethnicity, BMI, smoking and drinking habits as covariate
padd: p-value from additive gene-environmental interactions analysis.
pmulti: p-value from multiplicative gene-environmental interactions analysis.positive subjects with genotype GG/GA by 4.38 times that
of T2DM-negative subjects carrying genotype AA. It had
been previously reported that diabetes is a positive factor
contributing to CAD/MI [30,31]. T2DM, accounting for the
majority of forms of diabetes, has also been considered a
common disorder and an important risk factor for cardio-
vascular disease [32]. Recently, a report in a Chinese popula-
tion also found that another genomic variant on 9p21 is
associated with a risk of T2DM [33]. This is thought to be
due to the CDKN2A and CDKN2B genes in this genomic
region inhibiting CDK4 and CDK6, which has been demon-
strated to influence β cell proliferation and mass, eventually
leading to diabetes [34-36]. Meanwhile, a study published in
2008 reported an interaction between poor glycemic control
and a 9p21 variant that increased the risk of CAD in T2DM
[21]. Therefore, it is reasonable to consider that CDKN2A/B
(rs10757274) not only increases the risk of MI, but also en-
hances the effects of T2DM on the risk of MI in this study.
In contrast to CDKN2A/B (rs10757274), we found that
the genetic variant of ADTRP (rs6903956) on 6p24 was
not associated with MI after adjusting for conventional
confounding factors, which is inconsistent with recent
research results reported in a Japanese population [37].
To our knowledge, only this solo Japanese research re-
port has investigated the association between ADTRP
(rs6903956) and MI to date, and the risk allele identified
in this Japanese study differs from our study and two
other studies conducted in Han Chinese and Japanese
populations [14,38]. Most former studies have focused
on the identification of associations between ADTRP
and CAD, but the results are controversial even in the
same racial population [14,39,40]. It has been indicated
that the underlying mechanism is due to regulation of
the mRNA expression of the tissue factor pathway in-
hibitor (TFPI) by the ADTRP gene. Decreased TFPI ex-
pression would result in an increased rate of thrombosis
and thus increase the risk of CAD [41]. Therefore,actions analysis between T2DM and CDKN2A/B
) ORadd
a (95% CI) padd ORmulti
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genetic variants on 6p24 are associated with the risk of
MI.
There are inevitably some limitations to this study.
First, as our study is based on a case–control design, it
was difficult to avoid recall bias completely, and the re-
sults should be confirmed in prospective cohort studies.
Second, our study investigated only a limited number of
genetic variants related to MI, whereas many other
genes and SNPs have been reported to contribute to MI
susceptibility. Therefore, this study is not sufficient to
evaluate genetic susceptibility to MI, and it would be
useful for further studies to investigate more genetic
polymorphisms associated with MI.
Conclusion
In conclusion, the results of this study suggest that a
gene polymorphism of CDKN2A/B (rs10757274) is asso-
ciated with MI risk in a Chinese population. Further-
more, T2DM is likely to interact with CDKN2A/B
(rs10757274) and contribute to the risk of MI.
Additional file
Additional file 1: Table S1. Univariate associations between rs6903956
and the characteristics listed in Table 1 for cases and controls. Table S2.
Univariate associations between rs10757274 and the characteristics listed
in Table 1 for cases and controls.
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